Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis

Clinical trial NCT07612280 · RECRUITING

Trial details

NCT number: NCT07612280
Sponsor: Jubilant Therapeutics Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Essential Thrombocythemia (ET)Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)Myeloproliferative Neoplasms (MPN)

Start date: 2024-10-21
Primary completion: 2028-06-15
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.